Piedmont Pharmaceuticals, LLC

Bayer Healthcare LLC

Idexx Laboratories, Inc.

Idexx Pharmaceuticals, Inc.

Bayer B.v.

William R Campbell

Kathleen G Palma

Neil E Paulsen

Roland H Johnson

Kenneth A Larson

Barry A Omilinsky

Neil E Paulson

Pharmaceutically acceptable single parasiticidal agent compositions of imidacloprid for oral delivery to mammals to systemically control targeted blood-sucking or blood-consuming parasites, such as fleas, ticks and certain species of helminthes and scabies.

Systemic treatment of blood-sucking and blood-consuming parasites by oral administration of a parasiticidal agent

Methods for treating and preventing otitis externa with a course of treatment consisting of as little as a single dose are provided. The methods are practiced by topical administration of compositions having a lipid carrier, such as liposomes and non-vesicular lipids, to the outer ear canal. Such compositions lack viscocity-enhancing celluloses or adhesives, and are preferably not in the form of a gel. Active agents useful for treating pain, inflammation, fungal or parasitic infestation and/or infections in the outer ear are co-administered in or with the composition.

Methods and compositions for rapid treatment of otitis externa

Compositions and methods for killing ectoparasites on a subject. Compositions containing a fatty acid ester, e.g., isopropyl myristate, effective for killing ectoparasites is described. Also described are compositions containing a fatty acid ester and a siloxane (e.g., decacyclomethicone). The compositions can also contain a mectin and/or a mycin, and S-methoprene. The compositions are useful against a variety of ectoparasites that afflict humans, animals, and plants, e.g., head lice, fleas, body lice, crab lice, scabies, ticks, and plant parasites.

Methods and compositions for treating ectoparasite infestation

Compositions and methods for killing ectoparasites on a subject. Compositions containing a fatty acid ester, e.g., isopropyl myristate, effective for killing ectoparasites is described. Also described are compositions containing a fatty acid ester and a siloxane (e.g. decacyclomethicone). The compositions can also contain a mectin and/or a mycin, and S-methoprene. The compositions are useful against a variety of ectoparasites that afflict humans, animals, and plants, e.g., head lice, fleas, body lice, crab lice, scabies mites, ticks, and plant parasites.

The present invention provides non-aqueous compositions which comprise a pharmacologically or biologically active compound, an emulsifier, a polyol, and benzyl alcohol. The compositions are useful for administering the pharmacologically or biologically active compounds which they contain to animals, plants, or ground surfaces. In preferred embodiments, the pharmacologically or biologically active compounds may be water-insoluble or water-labile. The compositions of the present invention allow these compounds to be solubilized and conveniently transported to a site of application in a non-aqueous form, and then diluted in an aqueous solution. In a particularly preferred embodiment, the compound is ivermectin and is administered in the drinking water of poultry. The compositions of the present invention may also contain multiple pharmacologically or biologically active compounds which are administered simultaneously. The present invention also provides methods of administering the compounds. In the most preferred embodiment, the compounds may be administered in the drinking water of animals to be treated with the pharmacologically or biologically active compound. In other embodiments, the compositions may be topically applied to the animals or plants to be treated, or sprayed onto plants, animals, or a ground surface to be treated with the active compounds.

Formulations and methods for administration of pharmacologically or biologically active compounds

Compositions and methods for killing ectoparasites on a subject. Compositions containing a fatty acid ester, e.g., isopropyl myristate, effective for killing ectoparasites is described. Also described are compositions containing a fatty acid ester and a siloxane (e.g. decacyclomethicone). The compositions can also contain a mectin and/or a mycin, and S-methoprene. The compositions are useful against a variety of ectoparasites that afflict humans, animals, and plants, e.g., head lice, fleas, body lice, crab lice, scabies, ticks, and plant parasites.

The present invention relates to pharmaceutical compositions for the sustained release of pharmacologically active compounds, and methods of their manufacture and use. The pharmaceutical compositions contain microcrystals of pharmacologically active compounds which are encapsulated within a phospholipid layer which contain a unique combination of phospholipids. The pharmaceutical compositions may be rendered suitable for injection. The microcrystals are of varying sizes. At least 50 percent of the microcrystals are from 0.5 &mgr;m and 3.0 &mgr;m in diameter, at least ten percent of the microcrystals are from 3.0 &mgr;m to 10 &mgr;m in diameter, and the composition may contain microcrystals which are greater than 10 &mgr;m in diameter. Methods of manufacturing the composition are disclosed, as well as various methods of administration.

Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use

The present invention relates to pharmaceutical compositions for the sustained release of pharmacologically active compounds and methods of their manufacture and use. Sustained release times of 10-12 days have been achieved with the present invention. The present invention provides microcrystal compositions. The microcrystals comprise pharmacologically active compounds and are contained within a phospholipid layer which contains a unique combination of phospholipids. The present invention may be applied to a wide range of pharmaceutical compositions which may be rendered suitable for injection. The microcrystals are of varying sizes. At least 50 percent of the microcrystals are from 0.5 &mgr;m to about 3.0 &mgr;m in diameter, at least ten percent of the microcrystals are from about 3.0 &mgr;m to about 10 &mgr;m in diameter, and the composition contains microcrystals which are greater than 10 &mgr;m in diameter. In preferred embodiments, at least about 1% of the microcrystals are greater than 10 &mgr;m in diameter. The compositions and methods are useful for treating respiratory diseases, infections, inflammation, and pain in a variety of mammals. The compounds and methods are also able to sharply reduce the toxicity of drug compounds.

Growing community of inventors

Jamestown, NC, United States of America

William R Campbell